Pyxis Oncology Inc (NASDAQ: PYXS) on Friday, soared 16.10% from the previous trading day, before settling in for the closing price of $3.23. Within the past 52 weeks, PYXS’s price has moved between $1.35 and $6.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 44.60%. With a float of $46.81 million, this company’s outstanding shares have now reached $59.42 million.
Let’s look at the performance matrix of the company that is accounted for 50 employees. In terms of profitability, gross margin is 81.52%, operating margin of -351.42%, and the pretax margin is -302.58%.
Pyxis Oncology Inc (PYXS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Pyxis Oncology Inc is 21.23%, while institutional ownership is 52.37%.
Pyxis Oncology Inc (PYXS) Latest Financial update
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.56 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.51) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 44.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 34.60% during the next five years compared to -118.72% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
Pyxis Oncology Inc (PYXS) is currently performing well based on its current performance indicators. A quick ratio of 9.53 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.26, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.20 in one year’s time.
Technical Analysis of Pyxis Oncology Inc (PYXS)
Pyxis Oncology Inc (NASDAQ: PYXS) saw its 5-day average volume 0.63 million, a negative change from its year-to-date volume of 0.63 million. As of the previous 9 days, the stock’s Stochastic %D was 60.48%. Additionally, its Average True Range was 0.20.
During the past 100 days, Pyxis Oncology Inc’s (PYXS) raw stochastic average was set at 71.21%, which indicates a significant decrease from 94.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.50% in the past 14 days, which was higher than the 67.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.53, while its 200-day Moving Average is $3.94. Nevertheless, the first resistance level for the watch stands at $3.95 in the near term. At $4.15, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.51. If the price goes on to break the first support level at $3.39, it is likely to go to the next support level at $3.03. The third support level lies at $2.83 if the price breaches the second support level.
Pyxis Oncology Inc (NASDAQ: PYXS) Key Stats
Market capitalization of the company is 222.83 million based on 58,888K outstanding shares. Right now, sales total 0 K and income totals -73,790 K. The company made 16,150 K in profit during its latest quarter, and -3,260 K in sales during its previous quarter.
